Weight Loss on GLP-1s · FormBlends network
Lose fat, keep muscle and hold the result while you're on a GLP-1.
Protein targets, resistance training basics, what to do at a plateau, and what the trials showed after people stopped. Three calculators with the formulas shown.
- -7.9% vs +6.9%
- STEP 4: kept semaglutide vs switched to placebo, weeks 20 to 68
- People who stayed on semaglutide kept losing. Those switched to placebo regained most of it.
- 1.2 to 1.6 g/kg
- daily protein range studied for weight loss
- The daily protein range studied for keeping muscle while losing weight.
- 3
- calculators: protein and energy, plateau check, maintenance plan
- Calculators for protein and energy, plateau checks and a maintenance plan.
Start here
Three ways in, depending on what you need right now
- 01Protein and energy calculatorMifflin-St Jeor energy estimate and a sourced protein range, split per meal.
- 02Plateaus on a GLP-1: what the trial curves show, and what a stall usually isWeight loss on these drugs slows by design. The trial curves are steep early and flatten by about a year.
- 03Browse guides9 pages, most recently updated October 2, 2026
Interactive
Calculators
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
CalculatorProtein and energy calculator
Mifflin-St Jeor energy estimate and a sourced protein range, split per meal.
CalculatorPlateau checker
Your weekly weights against an illustrative curve scaled to a STEP 1 or SURMOUNT-1 endpoint.
CalculatorMaintenance planner
STEP 4 and SURMOUNT-4 applied to your weight, plus a question list for your prescriber.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Guides
Plateaus on a GLP-1: what the trial curves show, and what a stall usually is
You'll get: Weight loss on these drugs slows by design. The trial curves are steep early and flatten by about a year.
Weight loss on semaglutide and tirzepatide slows by design. Here is when the published curves flatten, why four flat weeks is not a plateau, what to check, and when to involve your prescriber.
Guides
Maintenance and stopping: what STEP 4, SURMOUNT-4 and the STEP 1 extension measured
You'll get: Three trials followed people after the drug stopped. On average, half to two-thirds of the lost weight came back within a year.
The three trials that followed people after semaglutide or tirzepatide was withdrawn, with the numbers, what they do and do not tell you, and how to turn them into a conversation with your prescriber.
Nutrition
Protein targets on a GLP-1: the ranges, where they come from, and how to hit them on a small appetite
You'll get: The 2025 advisory sets 1.2 to 1.6 grams of protein per kilogram a day, or 80 to 120 grams, while losing weight.
The 2025 joint advisory range of 1.2 to 1.6 g/kg/day, the position stands and trials behind it, why the per-meal split matters more than the daily total when appetite is low, and who should have a clinician set the number.
Training
Resistance training on a GLP-1: the minimum that works, how to start, and how to progress
You'll get: Guidelines ask for strength work on two or more days a week. The 2025 GLP-1 advisory asks for three.
What the physical activity guidelines and the 2025 joint advisory ask for, what the meta-analyses show about protein plus lifting, a two-to-three-day starting programme with progression rules, and the safety notes specific to therapy.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching body composition, exercise and maintenance (213 in total).
- Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain
Endocrinol Metab (Seoul) · October 22, 2026 · PubMed 42908410
- Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice
Cardiol Rev · October 20, 2026 · PubMed 42897716
- Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes
Patient · October 16, 2026 · PubMed 42888373
- Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
Intern Med · October 15, 2026 · PubMed 42875211
- Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis
J Clin Endocrinol Metab · October 13, 2026 · PubMed 42867450
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
20 pages across 3 sections, each sourced to a label, a trial or a dated manufacturer page.
Guides
You'll get: 9 sourced pages, each with a plain-English opener
Weight loss on semaglutide and tirzepatide slows by design. Here is when the published curves flatten, why...
Nutrition
You'll get: 6 sourced pages, each with a plain-English opener
The 2025 joint advisory range of 1.2 to 1.6 g/kg/day, the position stands and trials behind it, why the...
Training
You'll get: 5 sourced pages, each with a plain-English opener
What the physical activity guidelines and the 2025 joint advisory ask for, what the meta-analyses show about...
Why this site exists
The pivotal GLP-1 trials came with diet and activity counselling that never makes it into the prescription: a 500 kcal/day deficit, 150 minutes a week of activity, regular visits. The DXA substudies showed that a share of the weight lost was lean tissue. The withdrawal trials showed what happens when the drug stops. Those three facts set the agenda here: protect lean mass, know what a normal curve looks like, and plan for maintenance before you need it.
How to read the numbers
Trial means are averages of hundreds of people on brand products at label doses. Half of those people did worse than the mean, and the range inside every arm was wide. Where this site applies a trial number to your weight it says so and shows the arithmetic. Compounded GLP-1 products are not FDA approved and are not interchangeable with brand products, and the trial numbers were not measured on them.